Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates

分组1 - Ionis Pharmaceuticals reported a quarterly loss of $0.61 per share, which was better than the Zacks Consensus Estimate of a loss of $1.15, representing an earnings surprise of +46.96% [1] - The company posted revenues of $157 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 21.23%, and showing an increase from $134 million in the same quarter last year [2] - Ionis Pharmaceuticals has surpassed consensus EPS estimates and revenue estimates for four consecutive quarters [2] 分组2 - The stock has gained approximately 110.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.18 on revenues of $141.77 million, and for the current fiscal year, it is -$2.10 on revenues of $857.58 million [7] - The Medical - Drugs industry, to which Ionis Pharmaceuticals belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]